S
Silvia Luchetti
Publications - 20
Citations - 1108
Silvia Luchetti is an academic researcher. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 12, co-authored 18 publications receiving 951 citations.
Papers
More filters
Journal ArticleDOI
Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning
Anna Maria Raiola,Alida Dominietto,Anna Ghiso,Carmen Di Grazia,Teresa Lamparelli,Francesca Gualandi,Stefania Bregante,Maria Teresa Van Lint,Simona Geroldi,Silvia Luchetti,Filippo Ballerini,Maurizio Miglino,Riccardo Varaldo,Andrea Bacigalupo +13 more
TL;DR: In conclusion, an MA conditioning regimen followed by haploidentical BMT with PT-CY results in a low risk of aGV HD and cGVHD and encouraging rates of TRM and DFS.
Journal ArticleDOI
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
Matteo G. Della Porta,Anna Gallì,Andrea Bacigalupo,Silvia Zibellini,Massimo Bernardi,Ettore Rizzo,Bernardino Allione,Maria Teresa Van Lint,Pietro Pioltelli,Paola Marenco,Alberto Bosi,Maria Teresa Voso,Simona Sica,Mariella Cuzzola,Emanuele Angelucci,Marianna Rossi,Marta Ubezio,Alberto Malovini,Ivan Limongelli,Virginia Valeria Ferretti,Orietta Spinelli,Cristina Tresoldi,Sarah Pozzi,Silvia Luchetti,Laura Pezzetti,Silvia Catricalà,Chiara Milanesi,Alberto Riva,Benedetto Bruno,Fabio Ciceri,Francesca Bonifazi,Riccardo Bellazzi,Elli Papaemmanuil,Armando Santoro,Emilio Paolo Alessandrino,Alessandro Rambaldi,Mario Cazzola +36 more
TL;DR: Somatic mutation in ASXL1, RUNX1, or TP53 is independently associated with unfavorable outcomes and shorter survival after allogeneic HSCT for patients with MDS and MDS/AML.
Journal ArticleDOI
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: An update
Andrea Bacigalupo,Alida Dominietto,Anna Ghiso,C Di Grazia,Teresa Lamparelli,Francesca Gualandi,Stefania Bregante,M. T. Van Lint,Simona Geroldi,Silvia Luchetti,Raffaella Grasso,Simonetta Pozzi,Nicoletta Colombo,Elisabetta Tedone,Riccardo Varaldo,A M Raiola +15 more
TL;DR: It is confirmed that a myeloablative conditioning regimen followed by unmanipulated haploidentical BMT with PT-CY, results in a low risk of acute and chronic GVHD and encouraging rates of TRM and overall survival, also for patients with active disease at the time of transplant.
Journal ArticleDOI
T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia.
Andrea Bacigalupo,Marisa Valle,Marina Podestà,Anna Pitto,Elena Zocchi,Antonio De Flora,Sara Pozzi,Silvia Luchetti,Francesco Frassoni,Maria Teresa Van Lint,Giovanna Piaggio +10 more
TL;DR: The ability of MSC to downregulate T-cell priming, proliferation, and cytokine release is deficient in patients with SAA, persists indefinitely after immunosuppressive therapy, but seems to be restored after BMT.
Journal ArticleDOI
DLI after haploidentical BMT with post-transplant CY
Anna Ghiso,A M Raiola,Francesca Gualandi,Alida Dominietto,Riccardo Varaldo,M. T. Van Lint,Stefania Bregante,C. Di Grazia,Teresa Lamparelli,Federica Galaverna,Alessandra Stasia,Silvia Luchetti,Simona Geroldi,Raffaella Grasso,Nicoletta Colombo,Almalina Bacigalupo +15 more
TL;DR: This study confirms that escalating doses of DLI can be given in the haploidentical setting with PT-CY, with a relatively low risk of acute GVHD, and response rates and survival are dependent on the underlying disease.